Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages


Pharmacists discuss the impact and alternatives amid red blood cell shortages in myelofibrosis treatment, highlighting challenges, patient outcomes, quality of life issues, and health care cost implications.

This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In this Pharmacy Times® peer exchange, led by Mahmoudjafar, the discussion delves into the challenges of red blood cell transfusion shortages for myelofibrosis patients. Davis highlights issues such as travel, typing delays, and the financial burden associated with transfusions. He provides impactful statistics on increased health care utilization and costs for transfusion-dependent patients.

Nachar suggests alternative treatments, including erythroid-stimulating agents, to mitigate transfusion requirements. Mancini emphasizes the pharmacist’s advocacy role in promoting blood drives to address shortages and discusses the delicate balance in treating anemia and the underlying disease.

This summary offers a concise overview of the profound impact of red blood cell transfusion shortages on myelofibrosis patients, underlining the pharmacist’s crucial role in advocacy and exploring alternative interventions.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig -
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
Video 12 - "Empowering RSV Patients: Essential Vaccine Education Resources"
Video 11 - "Unmet Needs in Prevention and Management of RSV"
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Related Content
© 2024 MJH Life Sciences

All rights reserved.